{"nctId":"NCT02519855","briefTitle":"Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)","startDateStruct":{"date":"2015-09-11","type":"ACTUAL"},"conditions":["Herpes Zoster"],"count":882,"armGroups":[{"label":"Concomitant Vaccination","type":"EXPERIMENTAL","interventionNames":["Biological: ZOSTAVAX™","Biological: Placebo to ZOSTAVAX™","Biological: Influenza Vaccine"]},{"label":"Nonconcomitant Vaccination","type":"EXPERIMENTAL","interventionNames":["Biological: ZOSTAVAX™","Biological: Placebo to ZOSTAVAX™","Biological: Influenza Vaccine"]}],"interventions":[{"name":"ZOSTAVAX™","otherNames":["V211"]},{"name":"Placebo to ZOSTAVAX™","otherNames":[]},{"name":"Influenza Vaccine","otherNames":["Fluzone, Vaxigrip"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Has history of varicella or residence in a VZV-endemic area for ≥30 years\n* Is male, female not of reproductive potential, or female of reproductive potential and has a negative pregnancy test and agrees to avoid becoming pregnant throughout the study\n\nExclusion Criteria:\n\n* Has history of hypersensitivity to any vaccine component\n* Has previously received any varicella or zoster vaccine\n* Has received an influenza vaccine for the 2015-16 season\n* Has history of Herpes zoster\n* Has received immunoglobulin, monoclonal antibodies, or any blood products within 5 months before study vaccination\n* Is pregnant or breastfeeding, or expecting to conceive during the study\n* Has used immunosuppressant therapy\n* Has known or suspected immune dysfunction\n* Has experienced Guillain-Barré syndrome within 6 weeks\n* Has severe thrombocytopenia or any other coagulation disorder","healthyVolunteers":true,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Antibody","description":"Anti-VZV antibodies were determined using a Glycoprotein Enzyme-linked Immunosorbent Assay. Baseline was Day 1 for the Concomitant group and Week 4 for the Nonconcomitant group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"206.0","spread":null},{"groupId":"OG001","value":"230.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"395.6","spread":null},{"groupId":"OG001","value":"482.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Fold Rise From Baseline in VZV gpELISA Antibody Titers","description":"Anti-VZV antibodies were determined using a Glycoprotein Enzyme-linked Immunosorbent Assay. Baseline was Day 1 for the Concomitant group and Week 4 for the Nonconcomitant group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"2.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers of H1N1-specific Influenza Virus Antibody","description":"Antibodies to H1N1-specific influenza virus hemagglutinin were measured using a Hemagglutinin Inhibition (HAI) assay. Antibody titers are the reciprocal of the highest dilution of serum that completely inhibited hemagglutinin.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.9","spread":null},{"groupId":"OG001","value":"50.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"207.3","spread":null},{"groupId":"OG001","value":"200.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers of H3N2-specific Influenza Virus Antibody","description":"Antibodies to H3N2-specific influenza virus hemagglutinin were measured using a Hemagglutinin Inhibition (HAI) assay. Antibody titers are the reciprocal of the highest dilution of serum that completely inhibited hemagglutinin.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.5","spread":null},{"groupId":"OG001","value":"31.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"298.8","spread":null},{"groupId":"OG001","value":"272.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers of B-Yamagata-specific Influenza Virus Antibody","description":"Antibodies to B-Yamagata-specific influenza virus hemagglutinin were measured using a Hemagglutinin Inhibition (HAI) assay. Antibody titers are the reciprocal of the highest dilution of serum that completely inhibited hemagglutinin.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.6","spread":null},{"groupId":"OG001","value":"12.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.7","spread":null},{"groupId":"OG001","value":"43.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers of B-Victoria-specific Influenza Virus Antibody","description":"Antibodies to B-Victoria-specific influenza virus hemagglutinin were measured using a Hemagglutinin Inhibition (HAI) assay. Antibody titers are the reciprocal of the highest dilution of serum that completely inhibited hemagglutinin.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.2","spread":null},{"groupId":"OG001","value":"10.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.9","spread":null},{"groupId":"OG001","value":"32.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":435},"commonTop":["Injection site pain","Injection site erythema","Injection site swelling","Injection site pruritus"]}}}